Following a path blazed by Genzyme and now followed by a number of other biotechs and pharmas, Glaxo Smith Kline has announced they will be opening a division dedicated to finding medical treatments for rare diseases.
GSK has generously provided drug for the ongoing Children’s Tumor Foundation-funded Phase Zero trial to assess lapatinib as a candidate treatment for NF2 vestibular schwannoma. The new GSK rare disease program comes in the wake of other program closures at GSK. We will watch this closely.
